NCT07081503View on ClinicalTrials.gov

Phase 1 Study of ADX-626 in Healthy Participants

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 14, 2025

Primary Completion Date

January 22, 2027

Study Completion Date

January 22, 2027

Conditions
Healthy Adult Participants
Interventions
DRUG

ADX-626

siRNA duplex oligonucleotide

DRUG

Placebo

Saline

Trial Locations (1)

SE1 1YR

Richmond Pharmacology, London

Sponsors
All Listed Sponsors
lead

ADARx Pharmaceuticals, Inc.

INDUSTRY